Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life

Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):972-7. doi: 10.1007/s00417-005-0218-x. Epub 2006 Jan 13.

Abstract

Background: Photodynamic therapy (PDT) has been used in the treatment of choroidal neovascularisation secondary to age-related macular degeneration (AMD). This study prospectively investigated patients' subjective change in visual function following PDT as treatment for AMD.

Methods: Eighty-two consecutive patients receiving PDT in Tasmania, Australia, between May and November 2003 were recruited. In conjunction with a comprehensive clinical examination, the Visual Function-14 (VF-14) questionnaire was administered. Final follow-up occurred between February and March 2005. The VF-14 was scored by traditional summary scoring and by Rasch analysis.

Results: Five of the 82 (6.1%) subjects recruited were excluded from analysis. PDT was performed on average 5.7+/-2.6 times per patient. Raw VF-14 scores tended towards being significantly lower at follow-up than at baseline (67.6+/-27.2 against 64.5+/-27.7; P=0.052), and did significantly deteriorate using a collapsed Rasch analysis (P=0.0102). Following treatment, 38 (47.5%) eyes had lost three or more Snellen lines of best-corrected visual acuity.

Conclusion: Patients undergoing PDT typically report reasonable visual function. In parallel with visual acuity, self-reported visual function may deteriorate slightly after PDT for AMD, but not as much as reported in untreated AMD.

MeSH terms

  • Aged
  • Female
  • Humans
  • Longitudinal Studies
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / physiopathology
  • Male
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use
  • Prospective Studies
  • Quality of Life*
  • Sickness Impact Profile
  • Surveys and Questionnaires
  • Verteporfin
  • Visual Acuity / physiology*

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin